Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248995 | 0.86 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2617526 | 0.86 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8516375 | 0.83 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9190895 | 0.81 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7943600 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL6129269 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16485222 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17805715 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29609169 | 0.79 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL6706765 | 0.79 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| US-10377789-B2 | Oligonucleotide and artificial nucleoside having guanidine bridge | OSAKA UNIVERSITY (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| EP-2899197-B1 | OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEOSIDE HAVING GUANIDINE BRIDGE | UNIV OSAKA (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170058074-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| CN-101443350-B | Macrocyclic compounds as antiviral agents | MSD ITALIA S.R.L. (IT) | 2015-11-25 | — | — | CN | disclosed |
| WO-2007081335-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-7002020-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050004174-A1 | Antibacterial agents | GORDEEV MIKHAIL F (US) | 2005-01-06 | — | — | US | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | GORDEEV MIKHAIL F (US) | 2002-12-05 | — | — | US | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PAICS, CDK4, OXA1L | KMT2A 1381/4885FABP5 4536/4885FABP7 3575/4885 |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | KMT2A 2665/4885FABP5 1230/4885FABP7 1973/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | KMT2A 2637/4885FABP5 1228/4885FABP7 1962/4885 |
| US-10377789-B2 | Oligonucleotide and artificial nucleoside having guanidine bridge | RNGTT, NSUN2, RNMT | KMT2A 3221/4885FABP5 3002/4885FABP7 3147/4885 |
| US-20050004174-A1 | Antibacterial agents | PAICS, OXA1L, PNKP | KMT2A 1573/4885FABP5 4452/4885FABP7 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.